During Friday trade, Consumer stocks were declining with shares of consumer staples companies in the S&P 500 slumping more than 0.5%. Shares of consumer discretionary firms in the S&P 500 also were sinking about 0.5%.
On Friday, Shares of Avon Products Inc. (NYSE:AVP), gained 1.20% to $6.72. The company exchanged hands with 25,943,664 shares as compared to its average daily volume of 14,989,500 shares. The company has the market capitalization of 2.92B.
Avon Products, Inc. manufactures and markets beauty and related products worldwide. It offers beauty products, such as skincare, and personal care products, in addition to fragrances and color cosmetics; and fashion and home products comprising of jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children’s products, and nutritional products.
Shares of Opexa Therapeutics, Inc. (NASDAQ:OPXA), declined -6.56% to $0.57, during its last trading session.
On May 12, Opexa Therapeutics stated financial results for the three months ended March 31, 2015 and offered an update on the Company’s recent corporate developments.
Recent highlights comprise:
- In April 2015, Opexa accomplished a rights offering and raised $13,804,140 in gross proceeds, before expenses, through subscriptions for 25,098,437 units, counting the exercise of over-subscription privileges. Each unit compriseed of one share of common stock and a warrant to purchase an additional share of common stock. Net proceeds, after deduction of fees and expenses, are predictable to be about $12 million.
- In March 2015, Opexa received a $3 million payment from Merck Serono (a division of Merck, Darmstadt, Germany).
- The payment, which was made as part of an amendment to an existing Option and License Agreement between the parties, provides support for the ongoing Phase 2b Abili-T clinical study of Tcelna® (imilecleucel-T), Opexa’s personalized immunotherapy in development for patients with secondary progressive MS (SPMS), in addition to the preparation and planning of potential Phase 3 studies.
- Based on the current activities of the Company and projected burn, Opexa believes it has sufficient liquidity into the fourth quarter of 2016. The Company anticipates this will support the completion and reporting of top line results for the Phase 2b Abili-T study of Tcelna in SPMS patients and the completion of the preclinical activities for OPX-212 in NMO, in addition to supporting general operations of the Company.
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases, such as neuromyelitis optica (NMO) based on its proprietary T-cell technology.
At the end of Friday’s trade, Shares of McDonald’s Corp. (NYSE:MCD), lost -0.57% to $95.93.
On May 4, McDonald’s President and Chief Executive Officer Steve Easterbrook declared the initial steps of the Company’s turnaround plan counting a restructuring of McDonald’s worldwide business and financial updates.
Starting July 1, 2015, McDonald’s will operate under a new organizational structure with the following market segments:
- S. - the Company’s largest segment, accounting for more than 40% of the Company’s 2014 operating income;
- International Lead Markets - established markets counting Australia, Canada, France, Germany and the U.K., which operate within similar economic and competitive dynamics, offer similar growth opportunities and collectively represented about 40% of the Company’s 2014 operating income;
- High-Growth Markets - markets with relatively higher restaurant expansion and franchising potential counting China, Italy, Poland, Russia, South Korea, Spain, Switzerland and the Netherlands. Together these markets accounted for about 10% of the Company’s 2014 operating income; and
- Foundational Markets - the remaining markets in the McDonald’s system, each of which has the potential to operate under a largely franchised model. Corporate activities will also be stated within this segment.
McDonald’s Corporation operates and franchises McDonald’s restaurants in the United States, Europe, the Asia/Pacific, the Middle East, Africa, Canada, and Latin America. The company’s restaurants offer various food products, soft drinks, coffee, and other beverages.
Finally, Baxter International Inc. (NYSE:BAX), ended its last trade with -0.80% loss, and closed at $66.61.
CTI BioPharma Corp. and Baxter International, declared data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29-June 2, 2015 in Chicago, Ill. Pacritinib is an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3. Data presented at ASCO (Abstract #LBA7006) show that contrast to best accessible therapy (exclusive of a JAK inhibitor), pacritinib therapy resulted in a significantly higher proportion of patients with spleen volume reduction and control of disease-related symptoms. Data were also selected for inclusion in the official ASCO Press Program.
Myelofibrosis is associated with significantly reduced quality of life and shortened survival. Spleen enlargement (splenomegaly) is a common and debilitating symptom of myelofibrosis. As the disease progresses, the body slows production of important blood cells and within one year of diagnosis the incidence of disease-related thrombocytopenia (very low blood platelet counts), severe anemia, and red blood cell transfusion requirements enhance significantly.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
